CNS Pharmaceuticals Inc. is a preclinical stage pharmaceutical company. The Company is focused on developing anticancer drug candidates for the treatment of brain and central nervous system tumors. The Company is focused on developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity. It results in the inhibition of DNA replication and repair, and Ribonucleic acid (RNA) and protein synthesis.